Subtype
Thyroid Gland Neoplasm
CI-CAN-00001600Explore in graph →
Non-malignant189 active trials10 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001600Explore in graph →
Clinical trials
891 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06275425 | Comparison of the Coughing Frequency of Remimazolam Total Intravenous Anesthesia Versus Inhalational Anesthesia | completed | N/A | 106 | Yonsei UniversityOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06269731 | Anxiety & Depression in Thyroid Cancer Patients | unknown | — | 159 | Assiut UniversityOTHER | 0 | Feb 21, 2024 | clinicaltrials |
| NCT06271044 |
| a. Reducing Radioiodine Treatment in Papillary Thyroid Cancer. RAILESS |
| active not recruiting |
| N/A |
| 61 |
| Helsinki University Central HospitalOTHER |
| 0 |
| Feb 21, 2024 |
| clinicaltrials |
| NCT00390325 | Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06134830 | Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine. | not yet recruiting | — | 100 | Assiut UniversityOTHER | 0 | Feb 6, 2024 | clinicaltrials |
| NCT06243965 | Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?(DSR-MTC) | completed | — | 246 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05675605 | A Study of TY-1091 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 248 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05962892 | A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma | recruiting | — | 600 | Beijing Friendship HospitalOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT04327999 | Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System | terminated | Phase 2 | 9 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT02244463 | A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | completed | Phase 1 / Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT00342446 | A Follow-up Study of Women Evaluated and Treated for Infertility | completed | — | 12,193 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2024 | clinicaltrials |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).(AcceleRET-MTC) | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06101043 | PECS II Block and Single Port Robot-assisted Transaxillary Thyroidectomy | unknown | N/A | 76 | Min Suk ChaeOTHER | 0 | Jan 5, 2024 | clinicaltrials |
| NCT01709435 | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 2 | Dec 22, 2023 | clinicaltrials |
| NCT06121271 | Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications | not yet recruiting | Phase 2 | 110 | University College, LondonOTHER | 0 | Dec 7, 2023 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT06146985 | Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer | unknown | Phase 2 | 67 | Ruijin HospitalOTHER | 0 | Nov 28, 2023 | clinicaltrials |
| NCT05989555 | Effects of Radioactive Iodine on the Immune System in Thyroid Cancer(SCIMITAR) | unknown | — | 30 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06124469 | UNN-RADS Scale for Diagnosing Lymph Node Metastasis in Patients With History of Thyroid Cancer | completed | — | 99 | Instituto Mexicano del Seguro SocialOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT05182931 | A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)(I-FIRST) | unknown | Phase 2 | 80 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05545852 | A Clinical Study of Transaxillary Endoscopic and Open Thyroidectomy for PTC | unknown | N/A | 290 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT06087068 | Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma | recruiting | Phase 2 | 140 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00719615 | Assess Vitamin D Levels in Those With & Without Thyroid Cancer | completed | — | 111 | University of NebraskaOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT06082180 | A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer | recruiting | Phase 3 | 1,199 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06079333 | NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)(NEO-ATACT) | recruiting | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06079723 | A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06067594 | Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma. | completed | — | 155 | Austral University, ArgentinaOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06068101 | Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer | completed | — | 274 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT06051747 | Patient-Customized Bioprinting Technology for Practical Regeneration of the Respiratory Tract (Trachea) | unknown | Phase 1 / Phase 2 | 1 | Ja Seong Bae, MD, phDOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT01659385 | Leptin Levels in Papillary Thyroid Cancer(LL-PTC) | completed | — | 18 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT02347683 | Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy | completed | — | 50 | University of NebraskaOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT05102292 | The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation | unknown | Phase 1 / Phase 2 | 25 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05994365 | Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma | recruiting | — | 380 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 16, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT00568438 | Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample | completed | — | 169 | Stanford UniversityOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT05830500 | Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma | recruiting | Phase 4 | 360 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 25, 2023 | clinicaltrials |
| NCT03300284 | Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer | completed | — | 186 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT02814032 | Proteomics of Papillary Thyroid Carcinoma | unknown | — | 32 | The Affiliated Hospital of Inner Mongolia Medical UniversityOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT02947035 | Molecular Testing to Direct Extent of Initial Thyroid Surgery | completed | Phase 2 | 100 | University of PittsburghOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05932121 | Cross-sectional Case and Control Study on Quality of Life, Appearance and Functions in PTC Via Different Surgical Approach | unknown | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT03986593 | Cryoablation of Bone Metastases From Endocrine Tumors | terminated | N/A | 17 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT01321554 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)(SELECT) | completed | Phase 3 | 392 | Eisai Inc.INDUSTRY | 23 | Jun 22, 2023 | clinicaltrials |
| NCT04619316 | Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition(ERRITI) | unknown | Phase 2 | 70 | University Hospital, EssenOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01511393 | An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) | enrolling by invitation | — | 6,750 | Novo Nordisk A/SINDUSTRY | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02303444 | An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors(RIFTOS MKI) | completed | — | 667 | BayerINDUSTRY | 19 | Jun 8, 2023 | clinicaltrials |
| NCT05873283 | Papillary Thyroid Cancer and Central Lymp Node Dissection | completed | — | 250 | Başakşehir Çam & Sakura City HospitalOTHER_GOV | 1 | May 24, 2023 | clinicaltrials |
| NCT04031339 | Study of Clinical Outcomes of Thyroid Cancer(ITCO) | unknown | — | 15,000 | University of Roma La SapienzaOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT04821336 | Cholesterol Metabolites Analysis in Human Thyroid and Iodine Resistance(OXYTHYR) | completed | — | 30 | Institut Claudius RegaudOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05824312 | HRQOL in Locally Advanced Thyroid Carcinoma(LATCQOL) | unknown | — | 80 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 23, 2024source: clinicaltrials